MedTrace Logo

Oral Anticoagulation in Hemodialysis

NCT03799822 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2020-11-03

No results posted yet for this study

Summary

The investigators refer to the trial with clinicaltrials.gov indentifier NCT02610933 entitled Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients.

After termination of this trial, included patients will be asked to participate in the extension trial by continuing the treament of their respective allocation arm. No new intervention will be done.

Conditions

Interventions

DRUG

Rivaroxaban 10 MG Oral Tablet

replacement of warfarin by rivaroxaban

DIETARY_SUPPLEMENT

MK-7 2000µg thrice weekly

dietary supplement of vitamin K2 MK-7 2000µg thrice weekly

DRUG

Vitamin K Antagonist - Drug

treatment with a vitamin K antagonist

Sponsors & Collaborators

  • Onze Lieve Vrouw Hospital

    lead OTHER

Principal Investigators

  • Rogier Caluwe, MD · OLV Hospital Aalst, Belgium

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2020-09-15
Completion
2020-10-01

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03799822 on ClinicalTrials.gov